CL2004000800A1 - Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova - Google Patents

Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova

Info

Publication number: CL2004000800A1
Authority: CL; Chile
Prior art keywords: propellifier; heterocicles; peroxisomes; ppar; underground
Prior art date: 2003-04-15

Application number

CL200400800A

Other languages

English (en)

Inventor

Bailey Paul Stuart Humph Simon

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-15

Filing date

2004-04-14

Publication date

2005-03-04

2004-04-14 Application filed by Pfizer filed Critical Pfizer

2005-03-04 Publication of CL2004000800A1 publication Critical patent/CL2004000800A1/es

Links

150000001735 carboxylic acids Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000001419 dependent effect Effects 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
210000002824 peroxisome Anatomy 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL200400800A 2003-04-15 2004-04-14 Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova CL2004000800A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46321303P	2003-04-15	2003-04-15

Publications (1)

Publication Number	Publication Date
CL2004000800A1 true CL2004000800A1 (es)	2005-03-04

Family

ID=33300053

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200400800A CL2004000800A1 (es)	2003-04-15	2004-04-14	Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova

Country Status (25)

Country	Link
EP (1)	EP1615899A1 (es)
JP (1)	JP2006523671A (es)
KR (1)	KR20060009846A (es)
CN (1)	CN1805943A (es)
AP (1)	AP2005003418A0 (es)
AR (1)	AR044514A1 (es)
AU (1)	AU2004230316A1 (es)
BR (1)	BRPI0409429A (es)
CA (1)	CA2521915A1 (es)
CL (1)	CL2004000800A1 (es)
EA (1)	EA200501462A1 (es)
EC (1)	ECSP056105A (es)
IS (1)	IS8033A (es)
MA (1)	MA27764A1 (es)
MX (1)	MXPA05010967A (es)
NL (1)	NL1025946C2 (es)
NO (1)	NO20055370L (es)
OA (1)	OA13157A (es)
PA (1)	PA8600201A1 (es)
PE (1)	PE20050415A1 (es)
TN (1)	TNSN05262A1 (es)
TW (1)	TW200510353A (es)
UY (1)	UY28266A1 (es)
WO (1)	WO2004092145A1 (es)
ZA (1)	ZA200508362B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005247473A1 (en) *	2004-05-25	2005-12-08	Metabolex, Inc.	Substituted triazoles as modulators of PPAR and methods of their preparation
SG159561A1 (en)	2005-05-09	2010-03-30	Achillion Pharmaceuticals Inc	Thiazole compounds and methods of use
JP5043120B2 (ja)	2006-10-30	2012-10-10	クロマセラピューティクスリミテッド	ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
ES2445049T3 (es)	2007-03-08	2014-02-27	Albireo Ab	Derivados del ácido 3-fenilpropiónico y su uso en el tratamiento de la enfermedad inflamatoria intestinal
US8183263B2 (en)	2007-05-22	2012-05-22	Achillion Pharmaceuticals, Inc.	Heteroaryl substituted thiazoles
US8106209B2 (en)	2008-06-06	2012-01-31	Achillion Pharmaceuticals, Inc.	Substituted aminothiazole prodrugs of compounds with anti-HCV activity
CA2728228A1 (en)	2008-07-14	2010-01-21	Gilead Sciences, Inc.	Oxindolyl inhibitor compounds
AU2009271003A1 (en)	2008-07-14	2010-01-21	Gilead Sciences, Inc.	Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
NZ602832A (en)	2008-07-14	2014-04-30	Gilead Sciences Inc	Fused heterocyclic hdac inhibitor compounds
AU2009276699A1 (en)	2008-07-28	2010-02-04	Gilead Sciences, Inc.	Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
KR20120031170A (ko)	2009-06-08	2012-03-30	길리애드 사이언시즈, 인코포레이티드	알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
ES2463826T3 (es)	2009-06-08	2014-05-29	Gilead Sciences, Inc.	Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina
DE102010055499A1 (de) *	2010-12-22	2011-06-16	W.C. Heraeus Gmbh	Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
ES2586213T3 (es)	2011-10-31	2016-10-13	Xenon Pharmaceuticals Inc.	Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
JP6014155B2 (ja)	2011-10-31	2016-10-25	ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
FR2982858B1 (fr) *	2011-11-18	2013-11-29	Rhodia Operations	Procede de fabrication de composes comprenant des fonctions nitriles
FR2984322B1 (fr) *	2011-12-16	2013-12-20	Rhodia Operations	Procede de fabrication de composes comprenant des fonctions nitriles
BR112014029161A2 (pt)	2012-05-22	2017-06-27	Genentech Inc	benzamidas n-substituídas e seu uso no tratamento de dor
BR112015000187A2 (pt)	2012-07-06	2017-06-27	Genentech Inc	benzamidas substituídas com n e métodos de uso das mesmas
BR112015022488A2 (pt)	2013-03-14	2017-07-18	Genentech Inc	triazolopiridinas substituídas e métodos de uso das mesmas
BR112015023397A2 (pt)	2013-03-15	2017-07-18	Genentech Inc	benzoxazois substituídos e métodos de uso dos mesmos
CR20160296A (es)	2013-11-27	2016-09-20	Genentech Inc	Benzamidas sustituidas y métodos para usarlas
EP3166939B1 (en)	2014-07-07	2019-06-05	Genentech, Inc.	Therapeutic compounds and methods of use thereof
WO2016191312A1 (en)	2015-05-22	2016-12-01	Genentech, Inc.	Substituted benzamides and methods of use thereof
MA42683A (fr)	2015-08-27	2018-07-04	Genentech Inc	Composés thérapeutiques et leurs méthodes utilisation
PE20181003A1 (es)	2015-09-28	2018-06-26	Genentech Inc	Compuestos terapeuticos y sus metodos de uso
CN108495851A (zh)	2015-11-25	2018-09-04	基因泰克公司	取代的苯甲酰胺及其使用方法
EP3854782A1 (en)	2016-03-30	2021-07-28	Genentech, Inc.	Substituted benzamides and methods of use thereof
SG11201903348UA (en)	2016-10-17	2019-05-30	Genentech Inc	Therapeutic compounds and methods of use thereof
WO2018175707A1 (en)	2017-03-24	2018-09-27	Genentech, Inc.	4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
EP3759098A1 (en)	2018-02-26	2021-01-06	Genentech, Inc.	Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en)	2018-03-30	2021-02-17	F. Hoffmann-La Roche AG	Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh)	2018-05-22	2020-01-16	瑞士商赫孚孟拉羅股份公司	治療性化合物及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60007592T2 (de) *	1999-09-30	2004-09-16	Pfizer Products Inc., Groton	Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
CA2438492A1 (en) *	2001-02-15	2002-08-22	Pfizer Products Inc.	Proliferative activator receptor (ppar) compounds

2004
- 2004-04-01 EA EA200501462A patent/EA200501462A1/ru unknown
- 2004-04-01 MX MXPA05010967A patent/MXPA05010967A/es not_active Application Discontinuation
- 2004-04-01 CA CA002521915A patent/CA2521915A1/en not_active Abandoned
- 2004-04-01 OA OA1200500283A patent/OA13157A/en unknown
- 2004-04-01 JP JP2006506478A patent/JP2006523671A/ja active Pending
- 2004-04-01 WO PCT/IB2004/001159 patent/WO2004092145A1/en not_active Ceased
- 2004-04-01 AP AP2005003418A patent/AP2005003418A0/xx unknown
- 2004-04-01 KR KR1020057019591A patent/KR20060009846A/ko not_active Ceased
- 2004-04-01 BR BRPI0409429-8A patent/BRPI0409429A/pt not_active IP Right Cessation
- 2004-04-01 AU AU2004230316A patent/AU2004230316A1/en not_active Abandoned
- 2004-04-01 CN CNA2004800167362A patent/CN1805943A/zh active Pending
- 2004-04-01 EP EP04725121A patent/EP1615899A1/en not_active Withdrawn
- 2004-04-12 PE PE2004000361A patent/PE20050415A1/es not_active Application Discontinuation
- 2004-04-13 AR ARP040101236A patent/AR044514A1/es unknown
- 2004-04-13 UY UY28266A patent/UY28266A1/es not_active Application Discontinuation
- 2004-04-14 CL CL200400800A patent/CL2004000800A1/es unknown
- 2004-04-14 PA PA20048600201A patent/PA8600201A1/es unknown
- 2004-04-14 NL NL1025946A patent/NL1025946C2/nl not_active IP Right Cessation
- 2004-04-14 TW TW093110410A patent/TW200510353A/zh unknown
2005
- 2005-09-15 IS IS8033A patent/IS8033A/is unknown
- 2005-10-14 EC EC2005006105A patent/ECSP056105A/es unknown
- 2005-10-14 TN TNP2005000262A patent/TNSN05262A1/fr unknown
- 2005-10-14 MA MA28552A patent/MA27764A1/fr unknown
- 2005-10-14 ZA ZA200508362A patent/ZA200508362B/en unknown
- 2005-11-14 NO NO20055370A patent/NO20055370L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AP2005003418A0 (en)	2005-12-31
MA27764A1 (fr)	2006-02-01
NO20055370D0 (no)	2005-11-14
TNSN05262A1 (fr)	2007-07-10
OA13157A (en)	2006-12-13
PA8600201A1 (es)	2005-02-04
EA200501462A1 (ru)	2006-04-28
NO20055370L (no)	2006-01-12
NL1025946C2 (nl)	2005-02-01
AR044514A1 (es)	2005-09-14
UY28266A1 (es)	2004-11-30
TW200510353A (en)	2005-03-16
PE20050415A1 (es)	2005-06-13
KR20060009846A (ko)	2006-02-01
CN1805943A (zh)	2006-07-19
ECSP056105A (es)	2006-03-01
NL1025946A1 (nl)	2004-10-18
CA2521915A1 (en)	2004-10-28
ZA200508362B (en)	2006-11-29
AU2004230316A1 (en)	2004-10-28
MXPA05010967A (es)	2005-11-28
WO2004092145A1 (en)	2004-10-28
WO2004092145A8 (en)	2005-05-12
JP2006523671A (ja)	2006-10-19
BRPI0409429A (pt)	2006-04-18
EP1615899A1 (en)	2006-01-18
IS8033A (is)	2005-09-15

Publication	Publication Date	Title
WO2009054390A1 (ja)	2009-04-30	チアゾリジンジオン化合物
CL2007002348A1 (es)	2008-08-08	Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
CL2007003854A1 (es)	2008-05-30	Compuestos derivados de ciclopamina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto, util en el tratamiento de desordenes mediados por la via de hedgehog, como cancer.
EA201170305A1 (ru)	2011-10-31	Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
WO2008097428A3 (en)	2008-09-25	Compounds and compositions as modulators of gpr119 activity
CL2007002841A1 (es)	2008-02-08	Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina.
CL2007001885A1 (es)	2008-01-25	Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis.
CL2012001722A1 (es)	2012-12-14	Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CL2007002197A1 (es)	2008-02-15	Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
CL2008002110A1 (es)	2008-10-24	Procedimiento para la modulacion del receptor acoplado a la proteina g gpr119 para administrar un compuesto derivado de piridinona y opcionalmente un agente terapeutico opcional para tratar diabetes mellitus.
EA200900877A1 (ru)	2010-02-26	Пиперидиновые агонисты gpcr
EA201170304A1 (ru)	2011-10-31	Аналоги глюкозозависимого инсулинотропного полипептида
DK2209778T3 (da)	2012-09-17	Pyridin-2-yl-amino-1, 2, 4-thiadiazolderivater som glucokinase-aktivatorer til behandling af diabetes mellitus
CL2008001049A1 (es)	2008-08-08	Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
BRPI0814252B8 (pt)	2021-05-25	composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
CL2011000478A1 (es)	2011-06-17	Compuestos derivados de 2-imidazol-propanamida sustituidos, activadores de glucoquinasa; composicion farmaceutica, util para tratar o retrasar la progresion o aparacion de la diabetes tipo ii o trastornos relacionados con la diabetes.
WO2007025613A3 (en)	2007-07-19	Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2007003962A3 (en)	2007-03-08	Gpcr agonists
WO2007003961A3 (en)	2007-03-01	Gpcr agonists
WO2009054423A1 (ja)	2009-04-30	オキサジアゾリジンジオン化合物
CL2007002187A1 (es)	2008-02-01	Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
ATE555105T1 (de)	2012-05-15	Heterocyclische fxr-bindende verbindungen
MX2012003389A (es)	2012-04-10	Moduladores de gpr40 de pirrolidina.
MY154798A (en)	2015-07-31	Fused cyclic compounds
CR11266A (es)	2010-03-22	Derivados de pirrolidin-2ona como moduladores del receptor de androgeno